COMPANY PROFILE

BrightHeart

Explore full profile

FDA-cleared AI for expert-level fetal heart screening in prenatal ultrasound

Paris, FranceFounded 2022Biotech & Life Sciences

Valuation $25–50M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About BrightHeart

BrightHeart is a Paris medtech company founded in October 2022 from the clinical insight of fetal cardiologists Dr Marilyne Levy and Dr Bertrand Stos, with CEO Cécile Dupont (Sofinnova Partners). Its B-Right AI Platform embeds expert-level fetal-heart screening into routine obstetric ultrasound—guiding views, checking exam completeness and flagging structural abnormalities suggestive of congenital heart defects (CHD)—without forcing clinicians to change how they scan. The company cites multiple FDA 510(k) clearances, peer-reviewed clinical evidence and detection performance above 96% in validated settings, addressing historically low prenatal CHD detection rates. After a €2 million Sofinnova seed in 2023, in January 2026 BrightHeart raised an €11 million Series A co-led by Odyssée Venture and GO Capital, with Sofinnova Partners, Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels and clinician angels, to commercialise in the US and expand across Europe. Sources: Tech.eu / Sofinnova / BusinessWire 8 Jan 2026; brightheart.ai.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Paris, France
Employees: 28
Open positions: None listed
Dealroom signal: 86.2/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Pregnancy, Biotechnology, Medical Imaging, Core AI, Femtech, Clinical Decision Support, AI for medical imaging, Physician Support Tools
Technology: Artificial Intelligence, Deep Tech
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jan 2026	$12M	$48M	Sofinnova Partners · Sacha Loiseau · SideAngels · John Gridley	↗
SEED✓Equity / VC	May 2023	$2.2M	$8.8M	Sofinnova Partners	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

BrightHeart website traffic

Latest recorded traffic for BrightHeart is 2.2K monthly website visits, down 24.1% over the last three months. BrightHeart's team grew 40% over the past year.

Latest monthly visits2.2K 3-month web change-24.1% 1-year team growth+40%

Monthly website visitsMay 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GLGleamerProviding imaging users a suite of Artificial Intelligence solutions covering a wide range of clinical applications	Saint-Mandé, France	Acquired	124	$45M	$119M
KEKeen EyeAnalyzes and reviews slide images	Paris, France	Closed
THTHERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care	Paris, France	Operational
CACallyopeMonitoring brain health through speech	Neuilly-sur-Seine, France	Operational
SOSonioAn AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations	Paris, France	Acquired
MAMATRICIS.AIImprove diagnosis and reduce errors	Paris, France	Operational
MIMindPeakMindPeak automates visual diagnosis, making microscopical analysis more accessible to support in accurate cancer diagnoses	Hamburg, Germany	Operational
RARaidiumRaidium foundation model: Radiology augmented GPT to tackle the complexity of precision medicine	Roubaix, France	Operational